VEGF蛋白表达及VEGF-2578C/A等位基因频率与非小细胞肺癌临床特征、预后的关系

目的 探讨血管内皮生长因子(vascular endothelial growth factor,VEGF)蛋白表达及VEGF-2578C/A等位基因频率与非小细胞肺癌(non-small cell lung cancer,NSCLC)临床特征、预后的关系。 方法 纳入中国人民解放军海军安庆医院2018年3月—2020年2月收治的NSCLC患者80例。收集患者的临床资料,包括性别、年龄、吸烟史、病理类型、临床分期、淋巴结转移、家族史、手术方式、化疗周期、化疗方案。采集癌组织,经免疫组化法测定癌组织中VEGF蛋白表达情况,经聚合酶链反应-限制性片段长度多态性技术测定VEGF-2578C/A等位基因的分布情况。分析VEGF蛋白表达、VEGF-2578C/A等位基因频率及癌旁组织与患者临床特征的关系。随访2年,根据患者的预后情况,分成生存组、死亡组。比较两组VEGF蛋白表达与VEGF-2578C/A等位基因的分布情况。 结果 在80例患者中,VEGF阳性49例(61.25%),癌旁组织阳性10例(12.50%)。VEGF阳性者的临床分期Ⅲ～Ⅳ、淋巴结转移占比显著高于VEGF阴性者(均P＜0.05)。在80例患者中,VEGF-2578C/A等位基因频率分别为CC型49例(61.25%),AA型6例(7.50%),CA型25例(31.25%)。其中CC型的临床分期Ⅲ～Ⅳ、淋巴结转移占比显著高于CA型(均P＜0.05)。通过电话随访2年,提示56例(70.00%)生存,24例(30.00%)死亡。死亡组VEGF阳性、VEGF-2578C/A等位基因CC型占比显著高于生存组(均P＜0.05)。 结论 非小细胞肺癌临床分期Ⅲ～Ⅳ、淋巴结转移患者的VEGF蛋白表达以阳性为主,VEGF-2578C/A等位基因主要为CC型,且VEGF蛋白阳性、CC型患者的预后更差。

Relationship of expression of VEGF protein and frequency of VEGF-2578C/A allele with clinical characteristics and prognosis of non-small cell lung cancer

Objective To explore the relation of expression of vascular endothelial growth factor (VEGF) protein and frequency of VEGF-2578C/A allele with the clinical features and prognosis of non-small cell lung cancer (NSCLC). Methods We enrolled 80 patients with NSCLC hospitalized in the PLA Navy Anqing Hospital from March 2018 to February 2020, and collected their clinical data, including gender, age, history of smoking, pathological type, clinical stage, lymph node metastasis, family history, surgical method, chemotherapy cycle, and chemotherapy regimen. The expression of VEGF protein in cancer tissues was determined by immunohistochemistry, and the distribution of VEGF-2578C/A alleles was determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The expression of VEGF protein, the frequency of VEGF-2578C/A allele, and the relationship between paracancerous tissue and the clinical characteristics of the patients were analyzed. The patients were followed up for 2 years, and then divided into the survival group and the death group according to their prognoses. The expression of VEGF protein and the distribution of VEGF-2578C/A alleles in the two groups were compared. Results Among the 80 patients, 49 (61.25%) were positive for VEGF, and 10 (12.50%) positive for paracancerous tissue. Patients positive for VEGF were in clinical stage Ⅲ-Ⅳ, and lymph node metastasis was significantly higher in patients positive for VEGF than in ones negative for VEGF (P<0.05). Among the 80 patients, the frequency of VEGF-2578C/A allele showed that there were 49 (61.25%) patients with CC genotype, 6 (7.50%) ones with AA genotype, and 25 (31.25%) ones with CA genotype. The proportions of clinical stage Ⅲ-Ⅳ and lymph node metastasis were significantly higher in patients with CC genotype than in ones with CA genotype (both P<0.05). 2-year telephone follow-up indicated that 56 (70.00%) patients survived and 24 (30.00%) died. The proportions of positive VEGF and VEGF-2578C/A allele/CC genotype were significantly higher in the death group than in the survival group (both P<0.05). Conclusion Positive expression of VEGF protein was prevailing in NSCLC patients with clinical stage Ⅲ-Ⅳ and lymph node metastasis. CC genotype was most common in VEGF-2578C/A allele; moreover, patients with positive expression of VEGF protein and CC genotype showed poorer prognoses.